Myriad Genetics (MYGN) Stock Price, News & Analysis

Company Overview

Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual’s risk for various hereditary conditions and to guide personalized treatment decisions. The company’s core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women’s health, neurology and pharmacogenomics to support more informed clinical decision-making.

Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities. Myriad’s Prolaris® test evaluates prostate cancer aggressiveness by measuring gene expression levels, while its EndoPredict® assay helps predict the likelihood of breast cancer recurrence. The company also provides pharmacogenomic profiling to identify how patients may respond to certain medications, aiding in more precise drug selection and dosing.

Founded in 1991 and headquartered in Salt Lake City, Utah, Myriad Genetics has expanded its presence internationally, serving healthcare providers in the United States, Europe, Canada, Australia and select markets in Latin America and Asia. The company operates a network of clinical laboratories and collaborates with academic institutions, biopharmaceutical firms and healthcare systems to advance genomic research and develop novel diagnostic solutions.

Under the leadership of President and Chief Executive Officer Mark C. Capone, Myriad continues to invest in research and development to broaden its test menu and drive innovation in precision medicine. The company’s strategic initiatives include expanding direct-to-physician and direct-to-consumer outreach, enhancing its data analytics capabilities and forging partnerships to integrate genetic insights into routine clinical practice.

Key Stats

• Today's Range: $4.00 to $4.38
• 50-Day Range: $4.09 to $5.29
• 52-Week Range: $3.75 to $8.59
• Volume: 761,044 shs
• Average Volume: 1.58 million shs
• Market Capitalization: $400.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.40
• Consensus Rating: Hold

Myriad Genetics Stock Analysis - MarketRank™

Myriad Genetics scored higher than 71% of companies evaluated by MarketBeat, and ranked 196th out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Hold

Consensus Rating

Myriad Genetics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 5 hold ratings, and 1 sell rating.

Upside Potential

Myriad Genetics has a consensus price target of $6.40, representing about 48.1% upside from its current price of $4.32.

Amount of Analyst Coverage

Myriad Genetics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Myriad Genetics are expected to grow in the coming year, from ($0.37) to ($0.27) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Myriad Genetics is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Myriad Genetics is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Myriad Genetics has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.94% of the float of Myriad Genetics has been sold short.

Short Interest Ratio / Days to Cover

Myriad Genetics has a short interest ratio ("days to cover") of 7.92.

Change versus previous month

Short interest in Myriad Genetics has recently decreased by 5.98%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Myriad Genetics does not currently pay a dividend.

Dividend Growth

Myriad Genetics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.0 / 5
• News Sentiment: -0.42

News Sentiment

Myriad Genetics has a news sentiment score of -0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 20 news articles for Myriad Genetics this week, compared to 4 articles on an average week.

Company Ownership

• Score: 4.4 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of Myriad Genetics in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $694,548.00 in company stock, which represents 0.1702% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Myriad Genetics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $694,548.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

1.90% of the stock of Myriad Genetics is held by insiders.

Percentage Held by Institutions

99.02% of the stock of Myriad Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/05/2026
• Today: 5/08/2026
• Bank of America Global Healthcare Conference 2026: 5/13/2026
• AGM 2026: 6/04/2026
• Goldman Sachs 47th Annual Global Healthcare Conference 2026: 6/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MYGN
• CIK: 899923
• Web: www.myriad.com
• Phone: (801) 584-3600
• Fax: 801-584-3640
• Employees: 2,700
• Year Founded: 1991

Price Target and Rating

• Average Price Target for Myriad Genetics: $6.40
• High Price Target: $8.50
• Low Price Target: $5.50
• Potential Upside/Downside: +50.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$365.90 million
• Net Margins: -48.24%
• Pretax Margin: -48.23%
• Return on Equity: -8.51%
• Return on Assets: -4.48%

Debt

• Debt-to-Equity Ratio: 0.36
• Current Ratio: 2.40
• Quick Ratio: 2.26

Sales & Book Value

• Annual Sales: $824.50 million
• Price / Sales: 0.49
• Cash Flow: $3.90 per share
• Price / Cash Flow: 1.09
• Book Value: $3.57 per share
• Price / Book: 1.19

Miscellaneous

• Outstanding Shares: 94,440,000
• Free Float: 92,649,000
• Market Cap: $401.84 million
• Optionable: Optionable
• Beta: 1.81